Compare ECF & STXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ECF | STXS |
|---|---|---|
| Founded | 1986 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 176.2M | 164.1M |
| IPO Year | N/A | 2004 |
| Metric | ECF | STXS |
|---|---|---|
| Price | $12.38 | $1.39 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 20.0K | ★ 530.7K |
| Earning Date | 01-01-0001 | 05-12-2026 |
| Dividend Yield | ★ 6.42% | N/A |
| EPS Growth | N/A | ★ 16.67 |
| EPS | ★ 0.46 | N/A |
| Revenue | N/A | ★ $29,346,617.00 |
| Revenue This Year | N/A | $28.22 |
| Revenue Next Year | N/A | $30.47 |
| P/E Ratio | $26.72 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.71 | $1.24 |
| 52 Week High | $13.85 | $3.59 |
| Indicator | ECF | STXS |
|---|---|---|
| Relative Strength Index (RSI) | 40.97 | 45.56 |
| Support Level | $12.15 | $1.30 |
| Resistance Level | $12.32 | $1.51 |
| Average True Range (ATR) | 0.15 | 0.06 |
| MACD | -0.04 | 0.01 |
| Stochastic Oscillator | 15.29 | 28.12 |
Ellsworth Growth and Income Fund Ltd operate as a closed-end, diversified management investment company. Its investment objective is to provide income and the potential for capital appreciation, which objectives the Fund considers to be relatively equal over the long term due to the nature of the securities in which it invests. The company invests in convertible and equity securities. It invests in various sectors, such as healthcare, financial services, computer software and services, energy and utilities, real estate investment trusts, semiconductors, telecommunications, business services, food and beverage, consumer products, transportation, consumer services among others.
Stereotaxis Inc is engaged in robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. The company's mission is the discovery, development, and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. The company's revenue generation is derived from the streams of Systems, Disposables, Royalty, and Sublease, of which a majority of revenue is generated from the Disposables, service, and accessories stream.